Developer docs
API playgroundTry for free, no card

Search company profiles

Bot Image

Full company profile

uuid0002tqt

Namestring
Bot Image
Legal namestring
Bot Image, Inc.
Websiteurl
botimageai.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Bot Image, Inc. is a medical imaging AI company that develops and commercializes ProstatID, an FDA 510(k)-cleared, CE Mark-certified, and UKCA-certified SaaS medical device for prostate cancer screening, detection, and diagnosis. The software analyzes biparametric MRI (bpMRI) studies—T2-weighted, diffusion-weighted imaging (DWI), and apparent diffusion coefficient (ADC) sequences—using a proprietary boosted parallel Random Forest (bpRF) ensemble algorithm trained on more than 1,000 biopsy-confirmed cases with over 6,000 pathology-verified biopsy points. ProstatID automatically detects, segments, and classifies suspicious lesions, appending colorized 2D overlays and 3D lesion visualizations directly to a facility's PACS in under five minutes with no manual workflow steps, and is cleared for use across GE, Siemens, and Philips 1.5T and 3.0T MRI platforms.

Short descriptiontext

Bot Image is a medical AI software company that develops ProstatID, an FDA-cleared SaaS platform using proprietary machine learning to detect, diagnose, and screen prostate cancer from biparametric MRI, serving hospitals, imaging centers, urology practices, and patients via platform partners and a direct-to-consumer channel.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersOmaha, United States
HQ citystring
Omaha
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
prostate cancer screening, AI medical imaging, radiology AI software, MRI diagnostics, cancer detection AI
Industry3 codes
PRIMARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHDAAAEAH
Medical Imaging AI
NAICS code1 code
  • Software Publishers513210
SIC code2 codes
  • Services-Prepackaged Software7372
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Imaging AI Software
Social media profiles3 records
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model2 records
1Per-Click SaaS Pricing
TypeUsage Based
Description

ProstatID is offered as a SaaS medical device AI software on a per-click or per-study basis. Healthcare facilities pay a per-case fee for each prostate MRI processed. The company states per-case cost is more than covered by additional billing associated with use of CAD and/or substitution of ProstatID over MRA or contrast.

botimageai.com
2Platform Distribution Revenue Share
TypeSubscription Recurring
Description

Bot Image provides software capacity and expansion through platform distributors (Blackford, TeraRecon, Ferrum) who bear all capacity costs. Bot Image pays a percentage of sales to these distributors for their worldwide sales force support. This model minimizes Bot Image's staffing requirements for customer service.

botimageai.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Others
Pricing details1 tier
1Per-case SaaS pricing for healthcare facilities
ModelUsage-basedBilling cadencePay-as-you-go
Notes

Low-cost per click service with minimal IT integration required. Contact sales for specific pricing. Per-case cost offset by additional CPT billing codes for CAD and 3D reconstruction.

botimageai.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Bot Image develops and sells ProstatID, an FDA-cleared, cloud-based AI software (SaaS medical device) that analyzes biparametric prostate MRI studies for the screening, detection, and diagnosis of prostate cancer. The software is offered on a per-click/per-study basis to hospitals, imaging centers, and urology practices, integrating with PACS systems via a zero-click workflow. A separate patient-facing service, DeepView Imaging, lets individual patients upload existing prostate MRIs for AI-supported analysis powered by ProstatID.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 93.6% standalone AUROC sensitivity-specificity vs. 75.9% for best participating radiologist in clinical studies
+5 more records
Product overview1 text field

Bot Image offers a focused product portfolio anchored by ProstatID, North America's first FDA-cleared AI software for prostate cancer screening, detection, and diagnosis. ProstatID is a SaaS medical device that integrates with healthcare facility PACS systems to provide AI-powered analysis of prostate MRI studies. The company also offers DeepView Imaging, a separate patient-facing pathway that enables patients with existing MRIs to access ProstatID-powered analysis.

Product and service2 records
1ProstatID
CategoryMedical Imaging AI Software (SaaS)
Description

FDA-cleared AI software (SaaS medical device) that analyzes biparametric prostate MRI studies (T2W, DWI, ADC) for the screening, detection, and diagnosis of prostate cancer. It automatically detects, segments, and classifies lesions, returns colorized 2D overlays and 3D visualizations with a Gleason-aligned risk index, and integrates with PACS via a zero-click workflow in under five minutes. Targeted at hospital radiology departments, imaging centers, and urology practices.

2DeepView Imaging
CategoryDirect-to-Consumer AI Imaging Service
Description

A separate, patient-facing service powered by ProstatID that allows patients (or their physicians) with an existing prostate MRI to upload DICOM files and receive an AI-supported analysis report with visual overlays for discussion with their treating radiologist, urologist, or clinician. Results are returned for physician discussion without requiring a referral.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-23
Description

DeepView Imaging is a separate patient-facing service powered by ProstatID. Through this partnership, patients can securely upload their prostate MRI and receive an AI-supported analysis report with visual overlays to share with their physician. DeepView Imaging is a service of Precision Prostate Consulting, LLC.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-03-18
Description

TeraReon's Eureka Clinical AI platform integrates ProstatID to provide clinicians with state-of-the-art AI and deep learning technology for prostate cancer screening and detection using bpMRI. This partnership enables deployment through TeraReon's established healthcare platform.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Blackford partnered with Bot Image to add ProstatID to their extensive AI portfolio. Blackford's CEO Ben Panter stated: 'Bot Image's commitment to the detection and management of prostate cancer is a great fit with our mission to improve the lives of patients by leveraging AI to drive healthcare efficiencies.' Blackford provides global distribution capacity for ProstatID.

Strategic tierSupportingTypeTechnology or Integration
Description

Ferrum is listed as a partner in Bot Image's ecosystem, appearing alongside Blackford and TeraRecon in the partnership section of the website.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Aidoc is a venture-backed radiology AI vendor offering FDA-cleared algorithms across multiple imaging modalities (CT, MRI, X-ray) sold to hospitals and distributed through the same AI platform partners (Blackford, TeraRecon). Highly comparable in business model (per-study SaaS), GTM (enterprise + channel), and customer base (radiology departments, PACS-integrated workflows).

TypeDirect peer
Description

Lunit is a publicly traded Korean medical imaging AI company with FDA-cleared products in cancer detection (notably Lunit INSIGHT for mammography and chest), distributed via PACS partners globally. Closely comparable as a CAD/CADx AI vendor targeting radiologists with regulatory clearances in the US and EU.

TypeDirect peer
Description

Qure.ai develops deep-learning algorithms for medical imaging interpretation (head CT, chest X-ray, musculoskeletal) with multiple FDA clearances and CE marks, sold to hospitals and distributed through AI orchestration platforms including Blackford and TeraRecon. Direct comparable in regulatory strategy, channel GTM, and clinical workflow integration.

TypeDirect peer
Description

Viz.ai is a venture-scale radiology AI company focused on time-sensitive disease detection (stroke, PE, aortic disease) with FDA-cleared, PACS-integrated SaaS and a per-study commercial model. Comparable in target buyer (hospital radiology), regulatory pathway (510(k) CADe/CADx), and platform-partner distribution.

TypeDirect peer
Description

Avenda Health is an AI-focused prostate cancer company (Unfold AI for focal therapy planning) with FDA clearance and urology-channel sales. Closely comparable in therapeutic focus (prostate cancer), clinical buyer (urologists), and AI-imaging-for-cancer workflow, though it skews to treatment planning rather than MRI screening.

TypeDirect peer
Description

Paige is an AI company applying deep learning to cancer imaging (pathology, with adjacent imaging efforts) with FDA-authorized products sold to hospital pathology and oncology departments. Comparable as a regulated, AI-first cancer-imaging SaaS vendor with similar enterprise sales motion and CPT-driven economics.

TypeDirect peer
Description

DeepHealth, the AI subsidiary of RadNet, develops FDA-cleared imaging AI (mammography, prostate, lung) deployed across a large outpatient imaging network and offered to other providers. Comparable as a radiologist-facing AI imaging vendor with FDA clearances, channel partnerships, and per-study pricing.

TypeDirect peer
Description

Perspectum develops quantitative MRI AI software (notably LiverMultiScan) sold to hospitals and radiology groups with FDA clearance and CE marking. Comparable as a SaaS medical-device AI vendor using multiparametric MRI to deliver decision-support outputs integrated into radiology reporting workflows.

TypeDirect peer
Description

Quibim is a Spanish medical imaging AI company offering radiomics and AI-based image analysis across oncology (prostate, breast, lung) with CE-marked and FDA-cleared products distributed through enterprise channels. Comparable in imaging-AI focus on cancer, regulatory footprint, and partner-channel GTM.

10Zebra Medical Vision (Nanox)
TypeDirect peer
Description

Zebra Medical Vision (now part of Nanox) is an imaging-AI vendor with multiple FDA-cleared algorithms sold to hospitals on per-scan SaaS terms. Comparable as a multi-modality radiology AI vendor competing for the same hospital PACS integrations and using a similar pay-per-use commercial model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bot Image

Medical Imaging AI Softwarebotimageai.com

Bot Image is a medical AI software company that develops ProstatID, an FDA-cleared SaaS platform using proprietary machine learning to detect, diagnose, and screen prostate cancer from biparametric MRI, serving hospitals, imaging centers, urology practices, and patients via platform partners and a direct-to-consumer channel.

What Bot Image does

Bot Image, Inc. is a medical imaging AI company that develops and commercializes ProstatID, an FDA 510(k)-cleared, CE Mark-certified, and UKCA-certified SaaS medical device for prostate cancer screening, detection, and diagnosis. The software analyzes biparametric MRI (bpMRI) studies—T2-weighted, diffusion-weighted imaging (DWI), and apparent diffusion coefficient (ADC) sequences—using a proprietary boosted parallel Random Forest (bpRF) ensemble algorithm trained on more than 1,000 biopsy-confirmed cases with over 6,000 pathology-verified biopsy points. ProstatID automatically detects, segments, and classifies suspicious lesions, appending colorized 2D overlays and 3D lesion visualizations directly to a facility's PACS in under five minutes with no manual workflow steps, and is cleared for use across GE, Siemens, and Philips 1.5T and 3.0T MRI platforms.

Bot Image firmographics

Firmographics
Name
Bot Image
Legal name
Bot Image, Inc.
Website
https://botimageai.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
Bot Image is a medical AI software company that develops ProstatID, an FDA-cleared SaaS platform using proprietary machine learning to detect, diagnose, and screen prostate cancer from biparametric MRI, serving hospitals, imaging centers, urology practices, and patients via platform partners and a direct-to-consumer channel.
Ownership category
akta.pro rank

Bot Image industry classification

Industry
Product category
Medical Imaging AI Software
NAICS
Software Publishers (513210)
SIC
Services-Prepackaged Software (7372), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHDAAAEAH
Medical Imaging AI

Keywords

  • Prostate cancer screening
  • AI medical imaging
  • Radiology AI software
  • MRI diagnostics
  • Cancer detection AI

Where Bot Image is headquartered

Location

Headquarters

HQ city
Omaha
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Bot Image business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Others

Revenue model

  1. Per-Click SaaS Pricing: ProstatID is offered as a SaaS medical device AI software on a per-click or per-study basis. Healthcare facilities pay a per-case fee for each prostate MRI processed. The company states per-case cost is more than covered by additional billing associated with use of CAD and/or substitution of ProstatID over MRA or contrast.
  2. Platform Distribution Revenue Share: Bot Image provides software capacity and expansion through platform distributors (Blackford, TeraRecon, Ferrum) who bear all capacity costs. Bot Image pays a percentage of sales to these distributors for their worldwide sales force support. This model minimizes Bot Image's staffing requirements for customer service.

Pricing tiers

ModelBillingPrice
Usage-basedPay-as-you-goPer-case SaaS pricing for healthcare facilities

Go-to-market motion4 records

Distribution channels4 records

Marketing channels6 records

Bot Image product offering

Product offering

Core offering

Bot Image develops and sells ProstatID, an FDA-cleared, cloud-based AI software (SaaS medical device) that analyzes biparametric prostate MRI studies for the screening, detection, and diagnosis of prostate cancer. The software is offered on a per-click/per-study basis to hospitals, imaging centers, and urology practices, integrating with PACS systems via a zero-click workflow. A separate patient-facing service, DeepView Imaging, lets individual patients upload existing prostate MRIs for AI-supported analysis powered by ProstatID.

Product overview

Bot Image offers a focused product portfolio anchored by ProstatID, North America's first FDA-cleared AI software for prostate cancer screening, detection, and diagnosis. ProstatID is a SaaS medical device that integrates with healthcare facility PACS systems to provide AI-powered analysis of prostate MRI studies. The company also offers DeepView Imaging, a separate patient-facing pathway that enables patients with existing MRIs to access ProstatID-powered analysis.

Differentiator

Problem solved

Functional benefit

Products and services

  • ProstatID FDA-cleared AI software (SaaS medical device) that analyzes biparametric prostate MRI studies (T2W, DWI, ADC) for the screening, detection, and diagnosis of prostate cancer. It automatically detects, segments, and classifies lesions, returns colorized 2D overlays and 3D visualizations with a Gleason-aligned risk index, and integrates with PACS via a zero-click workflow in under five minutes. Targeted at hospital radiology departments, imaging centers, and urology practices.
  • DeepView Imaging A separate, patient-facing service powered by ProstatID that allows patients (or their physicians) with an existing prostate MRI to upload DICOM files and receive an AI-supported analysis report with visual overlays for discussion with their treating radiologist, urologist, or clinician. Results are returned for physician discussion without requiring a referral.

Quantifiable outcome

  • 93.6% standalone AUROC sensitivity-specificity vs. 75.9% for best participating radiologist in clinical studies
  • +5 more outcomes

Companies that use Bot Image

Customer profile

Named customers3 records

Segments5 records

Ideal customer profiles3 records

Bot Image technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability3 records

Feature6 records

Bot Image partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and supporting.

  • DeepView ImagingcoreStrategic or Co-development Partner · 23 January 2026DeepView Imaging is a separate patient-facing service powered by ProstatID. Through this partnership, patients can securely upload their prostate MRI and receive an AI-supported analysis report with visual overlays to share with their physician. DeepView Imaging is a service of Precision Prostate Consulting, LLC.
  • ConcertAI's TeraReconcoreTechnology or Integration · 18 March 2023TeraReon's Eureka Clinical AI platform integrates ProstatID to provide clinicians with state-of-the-art AI and deep learning technology for prostate cancer screening and detection using bpMRI. This partnership enables deployment through TeraReon's established healthcare platform.
  • BlackfordcoreChannel Partner/ Reseller/ DistributorBlackford partnered with Bot Image to add ProstatID to their extensive AI portfolio. Blackford's CEO Ben Panter stated: 'Bot Image's commitment to the detection and management of prostate cancer is a great fit with our mission to improve the lives of patients by leveraging AI to drive healthcare efficiencies.' Blackford provides global distribution capacity for ProstatID.
  • FerrumsupportingTechnology or IntegrationFerrum is listed as a partner in Bot Image's ecosystem, appearing alongside Blackford and TeraRecon in the partnership section of the website.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Bot Image competitors and assessment

Company assessment

Direct peers

  • Aidoc: Aidoc is a venture-backed radiology AI vendor offering FDA-cleared algorithms across multiple imaging modalities (CT, MRI, X-ray) sold to hospitals and distributed through the same AI platform partners (Blackford, TeraRecon). Highly comparable in business model (per-study SaaS), GTM (enterprise + channel), and customer base (radiology departments, PACS-integrated workflows).
  • Lunit: Lunit is a publicly traded Korean medical imaging AI company with FDA-cleared products in cancer detection (notably Lunit INSIGHT for mammography and chest), distributed via PACS partners globally. Closely comparable as a CAD/CADx AI vendor targeting radiologists with regulatory clearances in the US and EU.
  • Qure.ai: Qure.ai develops deep-learning algorithms for medical imaging interpretation (head CT, chest X-ray, musculoskeletal) with multiple FDA clearances and CE marks, sold to hospitals and distributed through AI orchestration platforms including Blackford and TeraRecon. Direct comparable in regulatory strategy, channel GTM, and clinical workflow integration.
  • Viz.ai: Viz.ai is a venture-scale radiology AI company focused on time-sensitive disease detection (stroke, PE, aortic disease) with FDA-cleared, PACS-integrated SaaS and a per-study commercial model. Comparable in target buyer (hospital radiology), regulatory pathway (510(k) CADe/CADx), and platform-partner distribution.
  • Avenda Health: Avenda Health is an AI-focused prostate cancer company (Unfold AI for focal therapy planning) with FDA clearance and urology-channel sales. Closely comparable in therapeutic focus (prostate cancer), clinical buyer (urologists), and AI-imaging-for-cancer workflow, though it skews to treatment planning rather than MRI screening.
  • Paige.AI: Paige is an AI company applying deep learning to cancer imaging (pathology, with adjacent imaging efforts) with FDA-authorized products sold to hospital pathology and oncology departments. Comparable as a regulated, AI-first cancer-imaging SaaS vendor with similar enterprise sales motion and CPT-driven economics.
  • DeepHealth (a RadNet company): DeepHealth, the AI subsidiary of RadNet, develops FDA-cleared imaging AI (mammography, prostate, lung) deployed across a large outpatient imaging network and offered to other providers. Comparable as a radiologist-facing AI imaging vendor with FDA clearances, channel partnerships, and per-study pricing.
  • Perspectum: Perspectum develops quantitative MRI AI software (notably LiverMultiScan) sold to hospitals and radiology groups with FDA clearance and CE marking. Comparable as a SaaS medical-device AI vendor using multiparametric MRI to deliver decision-support outputs integrated into radiology reporting workflows.
  • Quibim: Quibim is a Spanish medical imaging AI company offering radiomics and AI-based image analysis across oncology (prostate, breast, lung) with CE-marked and FDA-cleared products distributed through enterprise channels. Comparable in imaging-AI focus on cancer, regulatory footprint, and partner-channel GTM.
  • Zebra Medical Vision (Nanox): Zebra Medical Vision (now part of Nanox) is an imaging-AI vendor with multiple FDA-cleared algorithms sold to hospitals on per-scan SaaS terms. Comparable as a multi-modality radiology AI vendor competing for the same hospital PACS integrations and using a similar pay-per-use commercial model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Bot Image social profiles

Digital presence

Bot Image compliance and trust

Trust signal

Compliance4 records

Bot Image financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bot Image leadership team

Management profile

Number of profiles

Profiles9 records

Bot Image funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bot Image M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bot Image

What does Bot Image do?

Bot Image develops and sells ProstatID, an FDA-cleared, cloud-based AI software (SaaS medical device) that analyzes biparametric prostate MRI studies for the screening, detection, and diagnosis of prostate cancer. The software is offered on a per-click/per-study basis to hospitals, imaging centers, and urology practices, integrating with PACS systems via a zero-click workflow. A separate patient-facing service, DeepView Imaging, lets individual patients upload existing prostate MRIs for AI-supported analysis powered by ProstatID.

Is Bot Image a public or private company?

Bot Image is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Bot Image founded?

Bot Image was founded in 2019. It employs 1 to 10 people.

Where is Bot Image based?

Bot Image is headquartered in Omaha, United States, in the North America region.

How does Bot Image make money?

Two revenue lines are on record. Per-Click SaaS Pricing is the primary driver. The others are platform Distribution Revenue Share.

Who are Bot Image's main competitors?

Direct peers on record are Aidoc, Lunit, Qure.ai, Viz.ai, Avenda Health, Paige.AI, DeepHealth (a RadNet company), Perspectum, Quibim and Zebra Medical Vision (Nanox).

Does Bot Image have an API?

No public API is recorded for Bot Image.

What industry is Bot Image in?

Bot Image's product category is Medical Imaging AI Software. Its primary akta.pro industry code is HLAHABAJ, Radiology AI, CAD & Advanced Visualization Software, with a secondary code of HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML). Its NAICS code is 513210 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireBot Image, Inc. Earns UKCA Certification for ProstatID® AI Prostate MRI Software Under EU MDR 2002 No. 618Bot Image, Inc. announced that its ProstatID® AI prostate MRI software has received UKCA certification under EU MDR 2002, issued by Intertek Medical Notified Body AB (NB 2862) with effective date October 31, 2025 and expiry September 20, 2029. The certification covers image analysis software for the detection of prostate lesions and opens the UK market for what the company states is the first FDA-cleared AI platform for prostate MRI interpretation. The company indicated it will immediately begin onboarding European, UK, and other regional distributors and clinical partners to accelerate deployment across hospitals and diagnostic centers.PR NewswireBot Image, Inc. Earns UKCA Certification for ProstatID® AI Prostate MRI Software Under EU MDR 2002 No. 618Bot Image, Inc. announced that its ProstatID® AI prostate MRI software has received UKCA certification from Intertek Medical Notified Body AB (NB 2862) under the UK implementation of EU MDR 2002 No. 618, effective October 31, 2025 and expiring September 20, 2029. The certification confirms compliance with UKCA safety and performance requirements and positions ProstatID® as the first AI platform for prostate MRI interpretation to hold FDA, CE, and UKCA clearings. The company stated it will immediately begin onboarding European, UK, and other regional distributors and clinical partners to accelerate deployment across hospitals and diagnostic centers.SecSEC FORM DBot Image, Inc., a Nebraska-based corporation, filed a Form D notice with the SEC on October 20, 2025, reporting an exempt offering of equity and debt securities under Rule 506(b). The offering totaled $1,034,062 USD, with all securities sold and $0 remaining, with the first sale occurring on December 16, 2023. This is a routine regulatory filing with no material news value.SecSEC FORM DBot Image, Inc., a Nebraska corporation, filed a Form D notice with the SEC on October 20, 2025, for an exempt offering of equity and debt securities under Rule 506(b). The company is seeking to raise up to $1,000,000 and has already sold $280,000 in securities to one investor, with $720,000 remaining. The filing, signed by CEO Randall Jones, represents a routine regulatory notification rather than a significant corporate development.GlobeNewswireKoelis Announces Partnership with Bot Image™ at AUA 2025Koelis announced a partnership with Bot Image to combine its Trinity MRI-fusion guidance with Bot Image's FDA-cleared ProstatID AI software for prostate fusion biopsy. The collaboration aims to improve accuracy and workflow efficiency, with Koelis holding live demos at AUA 2025. The partnership reinforces Koelis' commitment to prostate biopsy precision.PR NewswireBot Image, Inc. Announces Verification of CPT payment code for its 3D Reconstruction of Prostate Tumors detected using bpMRIBot Image, Inc. announced that its ProstatID software has received verification of CPT payment codes from Medicare and United Healthcare for 3D reconstruction of prostate tumors. This development follows the FDA clearance granted to the AI medical device in June 2022, confirming its reimbursement eligibility for clinical use.PR NewswireBot Image, Inc. introduced its Prostate Cancer detection, diagnosis, and screening software at urologist meeting in San Antonio, TexasBot Image, Inc., a Nebraska and Maine-based AI medical device company, introduced its FDA-cleared ProstatID™ prostate cancer detection software at the AUA meeting in San Antonio, Texas, receiving positive feedback from attending urologists. The software demonstrated 93.6% AUROC performance and provides lesion detection, segmentation, and classification with PI-RADS scoring and risk assessment on a continuous scale from 1-99. A leading urologist who tested the software stated it had the most significant impact on prostate cancer detection and treatment planning among all products at the meeting, recommending that all urologists should use ProstatID.PR NewswireRenowned Urologist Endorses ProstatID as Game-Changer in Prostate Health AssessmentDr. D. Russell Locke, a urologist at Vantage Urologic Institute, has published an endorsement praising Bot Image Inc.'s ProstatID software as a game-changer in prostate health assessment, claiming it detects previously unidentified cancerous lesions and improves biopsy precision. The doctor reports using ProstatID to identify cancerous lesions that conventional MRI scans missed, and says its 3D outputs have enhanced his biopsy procedures. Bot Image Inc. released the endorsement as promotional content for its diagnostic tool.GlobeNewswireBlackford and Bot Image Announce Partnership to Enhance Prostate Cancer CareBlackford and Bot Image announced a commercial partnership to integrate Bot Image's ProstatID prostate cancer detection software into Blackford's AI platform. ProstatID is a radiological CADe/CADx device for MR scans from Philips, Siemens, and GE. The partnership aims to accelerate distribution to healthcare providers for early detection.PR NewswireRevolutionizing Prostate Cancer Care with Bot Image's ProstatID™ and bpMRIBot Image Inc., a Nebraska-based medical device company, has announced the availability of its FDA-cleared ProstatID AI-driven medical software used with bi-parametric MRI for prostate cancer screening, detection, diagnosis, and management. The technology offers early detection capabilities, guided precision biopsies, and personalized treatment planning while reducing overtreatment risks. This appears to be a product launch announcement for a prostate cancer diagnostic tool that emphasizes improved patient outcomes and care efficiency.